目的 寻找高活性、低毒性的新型抗肿瘤药物。方法 以(S)-(+)-扁桃酸和2-氨基苯甲酰胺为原料,经过缩合、分子内环化、氧化、氯化、偶联等反应,共设计合成19个2-取代-4-氨基喹唑啉衍生物,经1H-NMR、13C-NMR和19F-NMR进行了结构确证。采用MTT法测定了目标化合物对PC-3、A549、K562、MDA-231和HeLa 5种肿瘤细胞的体外生长抑制活性。结果 测试结果显示,部分目标化合物对上述5种肿瘤细胞均有不同程度的生长抑制作用。其中,化合物8a对HeLa细胞、8b和8c对K562细胞具有显著的抑制作用,半数抑制浓度(IC50)分别为3.05、3.31、2.03 μmol·L-1。结论 本实验合成的目标化合物大多数具有一定的抗肿瘤活性,可为多样化2-取代-4-氨基喹唑啉类抗肿瘤药物的设计合成提供参考依据。
Abstract
OBJECTIVE To find efficient and low toxicity anti-tumor drugs. METHODS A series of novel 2-substituted-4-aminoquinazoline derivatives were designed and synthesized starting from (S)-(+)-mandelic acid and 2-aminobenzamide by condensation, intramolecular cyclization, oxidation, chlorination and coupling reaction. The structures of target compounds were identified by 1H-NMR, 13C-NMR and 19F-NMR. Their antitumor activities against PC-3, A549, K562, MDA-231 and HeLa cells were evaluated by using MTT assay. RESULTS The results showed that some of the target compounds displayed different degrees of inhibitory effects against the five cancer cells. Among them, 8a exhibited significant inhibitory effects against HeLa cells with a IC50 values of 3.05 μmol·L-1, 8b and 8c exhibited significant inhibitory effects against K562 cells with the IC50 values of 3.31 μmol·L-1 and 2.03 μmol·L-1 respectively. CONCLUSION Most of the target compounds synthesized show certain anti-tumor activity, which provide a basis for further research on the derivatives of 2-substituted-4-aminoquinazoline.
关键词
喹唑啉 /
抗肿瘤活性 /
含氟化合物 /
噻唑蓝法 /
合成
{{custom_keyword}} /
Key words
quinazoline /
antitumor activity /
fluorine-containing compound /
MTT assay /
synthesis
{{custom_keyword}} /
中图分类号：
R914.5
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] SIEGEL R L, MILLER K D, JEMAL A, et al. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(3): 145-164.
[2] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[3] MIAO L, GUO S T, LIN C M, et al. Nanoformulations for combination or cascade anticancer therapy [J]. Adv Durg Deliv Rev, 2017, 115: 3-22.
[4] JI Q, YANG D, WANG X, et al. Design, synthesis and evaluation of novel quinazoline-2, 4-dione derivatives as chitin synthase inhibitors and antifungal agents [J]. Bio Med Chem, 2014, 22(13): 3405-3413.
[5] HU J, ZHANG Y, DONG L, et al. Design, synthesis, and biological evaluation of novel quinazoline derivatives as anti-inflammatory agents against lipopolysaccharide-induced acute lung injury in rats [J]. Chem Biol Drug Des, 2015, 85(6): 672-684.
[6] SALAHI R, ABUELIZZ H A, GHABBOUR H A, et al. Molecular docking study and antiviral evaluation of 2-thioxo-benzo[g]quinazolin-4(3H)-one derivatives [J]. Chem Cent J, 2016, 10(1): 21-28.
[7] SELVAM T P, SIVAKUMAR A, PRABHU P, et al. Design and synthesis of quinazoline carboxylates against Gram-positive, Gram-negative, Fungal pathogenic strains, and Mycobacterium tuberculosis [J]. J Pharm Bioallied Sci, 2014, 6(3): 278-284.
[8] EMAMI L, FAGHIH Z, KHABNADIDEH S, et al. 2-(Chloromethyl)-3-phenylquinazolin-4(3H)-ones as potent anticancer agents; cytotoxicity, molecular docking and in silico studies [J]. J Iran Chem Soc, 2021, 18: 1877-1889.
[9] ARDIZZONI A, LOPREVITE M, TISEO M. Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer[J]. Curr Med Chem Anticancer Agents, 2004, 4(2):139-148.
[10] BONOMI P. Erlotinib: a new therapeutic approach for non-small cell lung cancer[J]. Expert Opin Investig Drugs, 2003,12(8):1395-1401.
[11] RYAN A J, WEDGE S R. ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity[J]. Br J Cancer, 2005, 92(1): 6-13.
[12] GEYER C E, FORSTER J, LINDQUIST D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer.[J]. N Engl J Med, 2006, 355(26): 2733-2743.
[13] TOMOMI S, SHUHEI S, KEITA T, et al. Spironolactone, a classic potassium-sparing diuretic, reduces survivin expression and chemosensitizes cancer cells to Non-DNA-Damaging anticancer drugs.[J]. Cancers, 2019, 11(10): 1550-1567.
[14] BELLI S, ESPOSITO D, SERVETTO A, et al. c-Src and EGFR inhibition in molecular cancer therapy: what else can we improve? [J]. Cancers, 2020, 12(6): 1489-1505.
[15] GARATTINI E, TERAO M. Increasing recognition of the importance of aldehyde oxidase in drug development and discovery[J]. Drug Metab Rev, 2011, 43(3):374-386.
[16] NENAD M, LLOYD K, WILLIAM R P, et al. Metabolism by aldehyde oxidase: drug design and complementary approaches to challenges in drug discovery[J]. J Med Chem, 2019, 62(24): 10955-10994.
[17] KASIBHATLA S, BAICHWAL V, CAI S X. MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps[J]. Cancer Res, 2007, 67(12): 5865-5871.
[18] JIANG L, GOTO M, ZHU Q, et al. Scaffold hopping-driven optimization of 4-(quinazolin-4-yl)-3,4-dihydroquinoxa-lin-2(1H)-ones as novel tubulin inhibitors[J]. ACS Med Chem Lett, 2019, 11(1): 83-89.
[19] RIGOREAU L, CALDWELL J J, WELSH E J, et al. Structure-based design of potent and selective 2-(quinazolin-2-yl)phenol inhibitors of checkpoint kinase 2[J]. J Med Chem, 2011, 54(2): 580-590.
[20] LIU K, YU J, YU G, et al. Synthesis and antitumor activities of 4-amino-2-trifluoromethyl quinazoline derivatives[J]. Chin Pharm J(中国药学杂志),2022,57(17):1430-1437.
[21] TUNG Y S, COUMAR M S, WU Y S, et al. Scaffold-hopping strategy: synthesis and biological evaluation of 5,6-fused bicyclic heteroaromatics to identify orally bioavailable anticancer agents[J]. J Med Chem, 2011, 54(8): 3076-3080.
[22] LEE H Y, CHANG J Y, NIEN C Y, et al. 5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors. part 2, the impact of bridging groups at position C-2[J]. J Med Chem, 2011, 54(24): 8517-8525.
[23] REGINA G L, BAI R, COLUCCIA A, et al. New pyrrole derivatives with potent tubulin polymerization inhibiting activity as anticancer agents including hedgehog-dependent cancer[J]. J Med Chem, 2014, 57(11): 6531-6552.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
贵州省高层次创新型人才培养计划资助(黔科合平台人才[2016]5678);贵州省科技计划项目资助(黔科合基础-ZK[2021] 一般070)
{{custom_fund}}
PDF(1069 KB)
